DR. THOMAS P MONATH, M.D.
Medical Practice at Finn Rd, Harvard, MA
License number
Massachusetts 75417
Category
Medical Practice
Type
Specialist
Address
Address
21 Finn Rd, Harvard, MA 01451
Phone
(978) 456-3645
Organization information
See more information about THOMAS P MONATH at bizstanding.comTHOMAS P. MONATH, M.D., LLC
21 Finn Rd, Harvard, MA 01451
Registration:
Nov 9, 2012
State ID:
001091933
Business type:
Domestic Limited Liability Company (LLC)
Soc signatorys:
Thomas P. Monath (Manager), 21 Finn Rd, Harvard, MA 01451 (Physical),Thomas P Monath (Soc signatory), 21 Finn Rd, Harvard, MA 01451 (Physical)
Agent:
Thomas P. Monath, M.d,21 Finn Rd, Harvard, MA 01451 (Physical)
Professional information
Diagnosis Of Flavivirus Infection
US Patent:
6682883, Jan 27, 2004
Filed:
Jul 19, 2001
Appl. No.:
09/910647
Inventors:
Thomas P. Monath - Harvard MA
Assignee:
Acambis, Inc. - Cambridge MA
International Classification:
C12Q 170
US Classification:
435 5, 435 71, 435 721, 4351733, 4352351, 435236, 435239
Abstract:
The invention provides methods and kits for use in diagnosing flavivirus infection.
Chimeric Flavivirus Vaccines
US Patent:
6696281, Feb 24, 2004
Filed:
Dec 1, 1999
Appl. No.:
09/452638
Inventors:
Thomas J. Chambers - St. Louis MO
Thomas P. Monath - Harvard MA
Farshad Guirakhoo - Melrose MA
Thomas P. Monath - Harvard MA
Farshad Guirakhoo - Melrose MA
Assignee:
Acambis, Inc. - Cambridge MA
St. Louis University - St. Louis MO
St. Louis University - St. Louis MO
International Classification:
C12N 701
US Classification:
4352351, 4352301, 435 691, 435 693, 4352361, 424 932, 4242181, 4241991, 4242041, 4242021, 4241921
Abstract:
A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that the prM-E protein of the second flavivirus is expressed.
Chimeric Flavivirus Vaccines
US Patent:
2004022, Nov 11, 2004
Filed:
Nov 4, 2003
Appl. No.:
10/701122
Inventors:
Thomas Chambers - St. Louis MO, US
Thomas Monath - Harvard MA, US
Farshad Guirakhoo - Melrose MA, US
Juan Arroy - S. Weymouth MA, US
Thomas Monath - Harvard MA, US
Farshad Guirakhoo - Melrose MA, US
Juan Arroy - S. Weymouth MA, US
International Classification:
A61K039/12, C12N007/00
US Classification:
424/199100, 435/235100
Abstract:
A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that the prM-E protein of the second flavivirus is expressed.
Vaccines Against Japanese Encephalitis Virus And West Nile Virus
US Patent:
2012020, Aug 9, 2012
Filed:
Oct 3, 2011
Appl. No.:
13/251424
Inventors:
Farshad Guirakhoo - Melrose MA, US
J. Jian Liu - Milpitas CA, US
John A. Catalan - Newton MA, US
Thomas P. Monath - Harvard MA, US
Konstantin V. Pugachev - Natick MA, US
J. Jian Liu - Milpitas CA, US
John A. Catalan - Newton MA, US
Thomas P. Monath - Harvard MA, US
Konstantin V. Pugachev - Natick MA, US
Assignee:
Sanofi Pasteur Biologics Co. - Cambridge MA
International Classification:
A61K 39/12, A61P 31/14, C12N 7/02, C12N 7/00, C12N 7/04, C07H 21/00, A61P 37/04
US Classification:
4242181, 536 231, 4352351, 435236, 435239
Abstract:
The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.
Immunization Against Clostridium Difficile Disease
US Patent:
2013017, Jul 11, 2013
Filed:
Apr 27, 2012
Appl. No.:
13/457821
Inventors:
Paul J. Giannasca - Westford MA, US
Zhenxi Zhang - Waltham MA, US
Wende Lei - Waltham MA, US
Thomas P. Monath - Harvard MA, US
Zhenxi Zhang - Waltham MA, US
Wende Lei - Waltham MA, US
Thomas P. Monath - Harvard MA, US
Assignee:
Sanofi Pasteur Biologics, LLC - Cambridge MA
International Classification:
A61K 39/08
US Classification:
4242391
Abstract:
The invention provides active and passive immunization methods for preventing and treating infection, which involve percutaneous administration of toxin-neutralizing polyclonal immune globulin, toxoids, or combinations thereof. Also provided by the invention are toxoids, toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce toxin-neutralizing polyclonal immune globulin.
Method For Preventing The Activation Of Inactive, Recombinant Helicobacter Pylori Apourease
US Patent:
5985631, Nov 16, 1999
Filed:
Sep 12, 1997
Appl. No.:
8/928081
Inventors:
Gopalan Soman - Belmont MA
William D. Thomas - Somerville MA
Thomas P. Monath - Harvard MA
William D. Thomas - Somerville MA
Thomas P. Monath - Harvard MA
Assignee:
OraVax-Merieux Co. - Cambridge MA
International Classification:
C12N 999, C12N 996, C12N 980, A01N 3718, C07K 100
US Classification:
435184
Abstract:
A method for preventing the activation of inactive, recombinant Helicobacter pylori apourease is presented. The method comprises contacting the apourease with a compound that modifies a sulfhydryl or lysyl residue of the urease. The covalently modified apourease is prevented from molecular aggregation.
Clostridium Difficle Toxins As Mucosal Adjuvants
US Patent:
5919463, Jul 6, 1999
Filed:
Oct 16, 1995
Appl. No.:
8/543708
Inventors:
William D. Thomas - Winchester MA
Thomas P. Monath - Harvard MA
Zhenxi Zhang - Cambridge MA
Francisco Javier Torres-Lopez - San Clemente, MX
Wende Lei - Cambridge MA
David M. Lyerly - Radford VA
James S. Moncrief - Christiansburg VA
Thomas P. Monath - Harvard MA
Zhenxi Zhang - Cambridge MA
Francisco Javier Torres-Lopez - San Clemente, MX
Wende Lei - Cambridge MA
David M. Lyerly - Radford VA
James S. Moncrief - Christiansburg VA
Assignee:
OraVax, Inc. - Cambridge MA
International Classification:
A61K 3908, A61K 3846
US Classification:
4242391
Abstract:
The invention features methods and compositions for inducing protective and/or therapeutic immune responses to an antigen in a mammal. In these methods, an antigen is administered to the mammal with a toxin of a Clostridium (e. g. , C. difficile), or a fragment or derivative thereof having adjuvant activity.
Vaccination Against Dengue Virus Infection
US Patent:
2008019, Aug 14, 2008
Filed:
Aug 9, 2006
Appl. No.:
12/063365
Inventors:
Thomas P. Monath - Harvard MA, US
Farshad Guirakhoo - Chaponost, FR
Niranjan Kanesa-thasan - Lexington MA, US
Thomas H. Ermak - Brookline MA, US
Jean Lang - Mions, FR
Remi Forrat - Serezin Du Rhone, FR
Farshad Guirakhoo - Chaponost, FR
Niranjan Kanesa-thasan - Lexington MA, US
Thomas H. Ermak - Brookline MA, US
Jean Lang - Mions, FR
Remi Forrat - Serezin Du Rhone, FR
Assignee:
Acambis Inc. - Cambridge MA
Sanofi Pasteur SA - Lyon Cedex 07
Sanofi Pasteur SA - Lyon Cedex 07
International Classification:
A61K 39/295, A61K 39/12, A61P 31/14
US Classification:
4241991, 4242021
Abstract:
This invention relates to methods and kits for use in vaccination against dengue virus infection.
Flavivirus Vaccines
US Patent:
2009019, Jul 30, 2009
Filed:
Dec 1, 2008
Appl. No.:
12/325864
Inventors:
Thomas P. Monath - Harvard MA, US
Farshad Guirakhoo - Melrose MA, US
Juan Arroyo - S.Weymouth MA, US
Konstantin Pugachev - Natick MA, US
Farshad Guirakhoo - Melrose MA, US
Juan Arroyo - S.Weymouth MA, US
Konstantin Pugachev - Natick MA, US
International Classification:
A61K 39/12, C12N 7/00, C12Q 1/70
US Classification:
4242181, 4352351, 435 5
Abstract:
The invention provides flavivirus vaccines and methods of making and using these vaccines.
Smallpox Vaccine
US Patent:
7115270, Oct 3, 2006
Filed:
May 27, 2003
Appl. No.:
10/445671
Inventors:
Richard A. Weltzin - Lunenburg MA, US
Thomas P. Monath - Harvard MA, US
Thomas P. Monath - Harvard MA, US
Assignee:
Acambis Inc. - Cambridge MA
International Classification:
A61K 39/285, C12N 7/00, C12N 7/02
US Classification:
4242321, 4352351, 435239, 4353201, 4241991
Abstract:
The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.